Objective Stool cultures are expensive and time consuming, and the positive rate of enteric pathogens in cases of nosocomial diarrhea is low. The 3-day rule, whereby clinicians order a Clostridium difficile (CD) toxin test rather than a stool culture for inpatients developing diarrhea >3 days after admission, has been well studied in Western countries. The present study sought to validate the 3-day rule in an acute care hospital setting in Japan. Methods Stool bacterial and CD toxin test results for adult patients hospitalized in an acute care hospital in 2008 were retrospectively analyzed. Specimens collected after an initial positive test were excluded. The positive rate and cost-effectiveness of the tests were compared among three patient groups. Patients The adult patients were divided into three groups for comparison: outpatients, patients hospitalized for ! 3 days and patients hospitalized for " 4 days. Results Over the 12-month period, 1,597 stool cultures were obtained from 992 patients, and 880 CD toxin tests were performed in 529 patients. In the outpatient, inpatient ! 3 days and inpatient " 4 days groups, the rate of positive stool cultures was 14.2%, 3.6% and 1.3% and that of positive CD toxin tests was 1.9%, 7.1% and 8.5%, respectively. The medical costs required to obtain one positive result were 9,181, 36,075 and 103,600 JPY and 43,200, 11,333 and 9,410 JPY, respectively. Conclusion The 3-day rule was validated for the first time in a setting other than a Western country. Our results revealed that the "3-day rule" is also useful and cost-effective in Japan.
Introduction
When inpatients in Japan develop fever, abdominal pain, and diarrhea, physicians often order a stool culture. However, carefully prepared hospital meals rarely cause food poisoning, and the major causes of diarrhea during hospitalization are adverse drug effects and tube feeding (1) . Moreover, most cases of infectious enteritis and colitis acquired for hospitalized patients who develop diarrhea >3 days (or 72 hours) after admission. This well-known clinical rule states that clinicians should not order stool cultures for these patients, but rather perform CD toxin tests, and that stool cultures should be restricted to outpatients and inpatients hospitalized for ! 3 days (4) (5) (6) . A number of studies of the positive rate and timing of stool cultures in Western countries established the 3-day rule, supporting its usefulness (7) (8) (9) (10) (11) (12) (13) (14) . In the present study, we retrospectively investigated stool cultures and CD toxin tests carried out at an acute care hospital over a 12-month period in order to evaluate the validity of the 3-day rule and its costeffectiveness by comparing differences in the rate of positive results according to the timing of the stool cultures and CD toxin tests.
Materials and Methods

Hospital setting and patients
This study was conducted at the National Center for Global Health and Medicine, an acute care tertiary hospital in Tokyo, Japan. The hospital had 885 beds, an average of 714 inpatients daily, 390,262 outpatients and 18,811 emergency room visits in the study period of April 2008-March 2009. The study protocol was approved by the Ethics Committee of the National Center for Global Health and Medicine.
We retrospectively extracted the data for all stool culture and CD toxin tests performed in 2008, except for those conducted in the pediatrics department and in patients <15 years of age. First, we noted the results of the stool culture and CD toxin tests, irrespective of the timing of the tests. Next, in order to evaluate the validity and usefulness of the 3-day rule in our study population, we excluded cases with the following characteristics: 1) patient hospitalized before December 31, 2007; 2) specimens submitted after the initial positive results, in order to eliminate follow-up tests; and 3) invalid CD toxin tests due to insufficient amounts of the specimen. We then investigated the following patient demographics and test data: 1) outpatient versus inpatient; 2) days after admission (the date of admission was considered to be day 0); 3) age and sex; 4) recovery of an enteric pathogen via stool culture; and 5) the results of the CD toxin tests.
Data analysis
In order to assess the validity of the 3-day rule, we compared the positive rates of the stool culture and CD toxin tests according to the number of days from admission. We also compared the total number of samples, the number of positive samples, the rate of positive results (with a 95% confidential interval), the medical costs of the tests and the medical cost per one positive result among three patient groups: outpatients, patients hospitalized for ! 3 days and patients hospitalized for " 4 days. Based on Japanese health insurance costs in 2008, we calculated that an aerobic stool culture costs 1,300 JPY and a CD toxin test costs 800 JPY (100 JPY is roughly equivalent to 1 USD). We calculated the medical costs per one positive result as follows: (medical cost of each test × the number of total samples)/(the number of positive samples). The 95% confidential interval for the rate of positive results, using 95% Wald's confidential intervals, was calculated according to the following formula:
where n is the number of samples and p is the positive rate.
Bacterial test method
The stool cultures were performed according to standard laboratory methods. Blood agar, bromothymol blue agar, O157TAM agar, thiosulfate citrate bile salts sucrose (TCBS) agar, citrate bile salts sucrose agar and Skirrow's medium were used for the stool cultures obtained from all outpatients and inpatients hospitalized due to suspected infectious colitis. Cefsulodin-irgasan-novobiocin agar and SS/O157 extra agar were additionally used in patients with bloody stools. For stool cultures obtained from inpatients, TCBS agar and Skirrow's medium were omitted unless requested by the physician. When the specimens in an anaerobic porter were submitted for the culture of CD, cycloserinecefoxitin mannitol agar was used. The CD toxin test was performed using the TOX A/B QUIK CHEK test "NISSUI" (Nissui Pharmaceutical Co., Ltd, Tokyo, Japan).
Bacteria defined as enteric pathogens
Based on previous studies, we defined enteric pathogens as follows: Aeromonas species (sp.), Campylobacter sp., Salmonella sp., Vibrio sp., Klebsiella oxytoca, Yersinia sp., Shigella sp., Plesiomonas sp., Clostridium sp. and pathogenic Escherichia coli (4, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The recovery of enteric pathogens was considered to indicate a positive stool culture result. Enterococcus sp., E. coli, methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa were not included in the group of enteric pathogens. As K. oxytoca is known to cause hemorrhagic colitis due to antibiotic therapy (17, 18) , we reviewed the medical records to determine whether each patient had bloody diarrhea compatible with hemorrhagic colitis caused by K. oxytoca.
Results
Description of the specimens
The distribution of bacterial species detected in all of the 2008 specimens is shown in Table 1 . Our laboratory received 1,627 specimens for stool bacterial culture from 997 patients. A total of 3,960 species, that is, an average of 2.4 species per specimen, were recovered. Among these, only 83 species from 81 specimens were considered to be enteric pathogens. In other words, 95% of the detected species were clinically irrelevant. No culture to detect CD was performed because anaerobic stool cultures were not ordered in the appropriate containers. Among 12 cases of K. oxytoca, only one patient with ulcerative colitis had hematochezia. Among 1,224 CD toxin tests in 623 patients, 120 (9.8%) were positive and 98 (8.0%) could not be examined due to an insufficient quantity of stool.
Evaluation of the 3-day rule
After exclusion, 1,597 stool cultures from 992 patients (57.8% men; median age 58 years among men and 61 years among women) and 880 CD toxin tests from 529 patients (58.3% men; median age 62 years among men and 64 years among women) were analyzed to validate the 3-day rule and the cost-effectiveness of the tests.
Although more than half of all stool cultures were performed in patients hospitalized for " 7 days, the positive rate was only 1.3% (Fig. 1) . In contrast, 69.6% (48/69) of the enteric pathogens were detected in outpatient specimens, which accounted for only 21% of all stool cultures.
Compared to that observed in the outpatients and patients hospitalized for ! 3 days, the positive rate for enteric pathogens was low (1.3%); therefore, the cost needed to detect one positive specimen was high (103,600 JPY) for patients hospitalized for " 4 days ( Table 2 ). Among 13 patients with enteric pathogens detected on a stool culture submitted " 4 days after admission, K. oxytoca was detected in six cases, pathogenic E. coli was detected in five cases and Aeromonas sp. was detected in two cases.
As for the CD toxin test, most specimens were submitted for inpatients, particularly those hospitalized for " 7 days, and most positive results were observed in these patients (Fig. 2) . The positive rate for the CD toxin test was higher among inpatients than outpatients, and the cost required to detect one positive specimen was approximately 10,000 JPY. Therefore, this test was much more cost-effective than the stool culture for patients hospitalized for " 4 days and more cost-effective than the CD test for outpatients ( Table 2) .
Discussion
Previous studies have reported that the rate of positive stool cultures in adult patients hospitalized for >3 days is low (0-4.8%), compared with the 2.0-18.4% observed in outpatients and inpatients hospitalized for ! 3 days or 72 hours (4, (7) (8) (9) (10) (11) (12) (13) (14) (Table 3 ). In contrast, specimens obtained from patients hospitalized for " 4 days have been reported to exhibit CD infection in 15-20% of cases (5). Practice guidelines for the management of infectious diarrhea issued by the Infectious Disease Society of America recommend that physicians order only CD toxin tests in patients with nosocomial diarrhea (5) . In cases of nosocomial outbreaks, bloody stools or infant diarrhea, stool cultures for Salmonella, Shigella, Campylobacter and E. coli O157: H7 should be added.
The present study showed that the stool culture had a low probability of positive results and low cost-effectiveness in patients who developed diarrhea during hospitalization. Therefore, the 3-day rule was validated in a Japanese acute care setting. To our knowledge, this is the first report of the validity of the 3-day rule in a country outside North America and Europe.
The positive rate of the stool culture can be affected by specimens  1  3  2  1  0  0  2  3  58   all  specimens  54  13  30  26  16  24  17  31  669 outpatients % patient characteristics, hospital settings, physician clinical practice patterns, the definition of enteric pathogens and laboratory procedures. The present study was conducted in a tertiary hospital in Tokyo, and standard techniques and media were used for the stool culture. We defined enteric pathogens based on previous studies of the 3-day rule and reports of outbreaks of Aeromonas sp. (15) and Plesiomonas sp. (16). Although MRSA (19, 20) and P. aeruginosa (21, 22) can cause diarrhea, we excluded these pathogens because most previous studies did not consider them to be causative organisms. We identified 12 recovery cases of K. oxytoca, a known causative pathogen of hemorrhagic colitis due to antibiotic therapy (17, 18) . We were unable to determine the association between K. oxytoca and antibiotic treatment because the history of antibacterial therapy was unavailable. Although there is a possibility that K. oxytoca may cause diarrhea without hematochezia, all relevant cases were considered to be due to colonization because bloody diarrhea was not observed in any patients.
In spite of our relatively broader definition of enteric A: Adult, C: Child pathogens, our findings were similar to those of other studies: a very low positive rate of stool cultures in patients hospitalized for ! 4 days. Our results indicate that the 3-day rule is useful and valid for assessing cases of adult diarrhea in areas other than Western countries. Although we excluded pediatric samples, some studies have shown that children have a higher positive rate of stool cultures than adults (12, 14) , while others have demonstrated comparable rates (4, 9) . At this time, it is therefore considered to be premature to apply the 3-day rule to children.
The medical cost to obtain one positive stool culture among patients hospitalized for ! 4 days was 103,600 JPY, which is approximately 10 times more expensive than the test used for outpatients. This low level of cost-effectiveness was due to the low prevalence of bacterial infection other than CD in the patients with nosocomial diarrhea. Our cost analysis was simple and did not include the costs for laboratory staff, reagents, anaerobic cultures, tests for susceptibility to antibiotics and therapy as a consequence of the test results, among other factors. However, by applying the 3-day rule in our hospital, we could have omitted over 1,000 stool cultures, considerably reducing the work load and saving 1.5 million JPY per year. A cost analysis of the 3-day rule has been previously conducted (3, 4, 7-14, 23, 24) . Similar to our results, the cost per one positive result in patients with nosocomial diarrhea was estimated to be 952-1,276 USD (3, 9) . By applying the 3-day rule in the USA, 27-73 million USD could be saved annually, and 100-300 person-years of laboratory work time could be allocated to more useful diagnostic work (23) . In the UK, the annual potential savings to the National Health Service has been estimated to be on the order of 1.18 million GBP (4) .
On the other hand, we found that the positive rate of the CD toxin test was much lower in outpatients than in inpatients, consistent with the findings of previous studies. The cost per one positive result among outpatients was as high as 43,200 JPY, while that among inpatients was only around 10,000 JPY. CD is one of the major pathogens of nosocomial infections, and preventive and therapeutic interventions, such as disinfection, the interruption of antibiotic therapy and the commencement of metronidazole or vancomycin, are necessary.
Although five years have passed since our study period, our findings remain valid because the standard techniques and media used for the stool cultures in our study have not recently changed. At the time of the study, the CD toxin test performed using an enzyme immune assay was more reliable because it was able to detect both toxin A and B. Moreover, the latest test can also detect glutamate dehydrogenase functioning as a CD antigen. The sensitivity and specificity of the test are reported to be 100% and 93.3%, respectively (25) . Therefore, with regard to clinical significance and cost-effectiveness, the CD test should be performed in cases of nosocomial diarrhea.
It should be noted that if the 3-day rule is automatically applied to all stool cultures, cases of bacterial diarrhea may be missed. We found enteric pathogens in patients hospitalized for ! 4 days. Although the clinical significance of these enteric pathogens was unclear due to a lack of sufficient medical information, no antibiotics against these bacteria were administered. The delayed diagnosis of a Salmonella outbreak due to the use of rejection criteria for stool cultures based on the 3-day rule has been reported (26) . Moreover, based on a survey of patients with enteric pathogens in stool cultures at ! 4 days after admission, a "modified 3-day rule" has been proposed (13) . Among patients ! 65 years of age with pre-existing comorbid disease, neutropenia (<500/ μL), HIV infection, or non-diarrheal manifestations of enteric infections, a stool culture should be performed on up to two occasions. Therefore, the 3-day rule should not be applied without consideration; instead the need for a stool culture should be based on the presenting symptoms, underlying disease and whether there is an epidemic of an infectious disease. Even if all patients with diarrhea undergo a stool culture without restriction, some enteric pathogens may be overlooked, such as Norovirus and Rotavirus. In order to detect the outbreak of nosocomial diarrhea early and intervene immediately, clinicians must not only conduct a thorough medical interview and physical examination combined with appropriate microbiological tests, but also employ a surveillance system and infection control team to analyze the results of bacterial tests and take preventive measures.
The present study has similar limitations to those of previous studies of the 3-day rule, as our aim was to validate this rule, and we consequently followed the design of previous studies. We were unable to investigate clinical information in detail, such as symptoms, underlying conditions, including gastrointestinal disease and immunity, laboratory data and the use of antibiotics, that may have influenced the bacteriological test results. Even the investigation of the "modified 3-day rule" included information limited to patients with positive results three days after admission. In spite of these limitations, we clearly showed a low rate of positivity of stool cultures among patients hospitalized for ! 4 days and thus confirmed the validity of the 3-day rule. Our results indicated a strong association between the timing and positive rate of both the stool cultures and CD toxin tests. We also determined the cost-effectiveness of the stool bacterial tests and increased the generalizability of the 3-day rule to a setting other than a Western country.
In conclusion, the 3-day rule can be used to estimate the pretest probability of a stool microbiological test and avoid unnecessary costs and labor in Japan. This rule is very useful, cost-effective and easy to follow for clinicians. Future prospective studies collecting sufficient and comprehensive clinical information to determine the predictive factors of a positive result other than the timing of the test are needed.
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